Signs and symptoms of Parkinson's disease

Last updated

Signs and symptoms of Parkinson's disease are varied. Parkinson's disease affects movement, producing motor symptoms. [1] Non-motor symptoms, which include dysautonomia, cognitive and neurobehavioral problems, and sensory and sleep difficulties, are also common. [1] When other diseases mimic Parkinson's disease, they are categorized as parkinsonism.

Contents

Motor signs and symptoms

Parkinson's disease patient showing a flexed walking posture pictured in 1892. Photo appeared in Nouvelle Iconographie de la Salpetriere
, vol. 5. Paralysis agitans-Male Parkinson's victim-1892.jpg
Parkinson's disease patient showing a flexed walking posture pictured in 1892. Photo appeared in Nouvelle Iconographie de la Salpètrière, vol. 5.
CS 000002 002 J1 199.jpg
Frontal view
Paralysis agitans-Woman with Parkinson's Disease-Nouvelle Iconographie de la Salpetriere-vol 2-pl29.jpg
Side view
Woman with paralysis agitans showing a characteristic type of extension. Photos were taken in 1889 and appeared in Nouvelle Iconographie de la Salpètrière, vol. 2.

Four motor symptoms are considered cardinal signs in PD: slowness of movement (bradykinesia), tremor, rigidity, and postural instability. [1] Typical for PD is an initial asymmetric distribution of these symptoms, where in the course of the disease, a gradual progression to bilateral symptoms develops, although some asymmetry usually persists. Other motor symptoms include gait and posture disturbances such as decreased arm swing, a forward-flexed posture, and the use of small steps when walking; speech and swallowing disturbances; and other symptoms such as a mask-like facial expression or small handwriting are examples of the range of common motor problems that can appear. [1]

Cardinal signs

Four motor signs are considered cardinal in PD: tremor, rigidity, bradykinesia, and postural instability (also referred to as parkinsonism). [1]

... immobile patients who become excited may be able to make quick movements such as catching a ball (or may be able to suddenly run if someone screams "fire"). This phenomenon (kinesia paradoxica) suggests that patients with PD have intact motor programmes, but have difficulties accessing them without an external trigger, such as a loud noise, marching music, or a visual cue requiring them to step over an obstacle. [1]

Other motor symptoms

Drawing of a Parkinson's disease patient face showing hypomimia. Depiction appeared in Nouvelle Iconographie de la Salpetriere
, vol 1 (1888). Drawing of face of parkinsons disease patient showing hypomimia.jpg
Drawing of a Parkinson's disease patient face showing hypomimia. Depiction appeared in Nouvelle Iconographie de la Salpètrière, vol 1 (1888).
Example of writing by a patient with Parkinson's disease, possibly showing micrographia in addition to other abnormal characteristics. published by Jean-Martin Charcot in 1879: Text accompanying image stated, "The strokes forming the letters are very irregular and sinuous, whilst the irregularities and sinuosities are of a very limited width. On a careful examination of this specimen of writing, it will be perceived that the down-strokes are all, with the exception of the first letter, made with comparative firmness and are, in fact, nearly normal--the finer up-strokes, on the contrary, are all tremulous in appearance, and it is to the unsteadiness of these lines that the peculiar character of the writing here is principally due." Writing by a Parkinson's disease patient.png
Example of writing by a patient with Parkinson's disease, possibly showing micrographia in addition to other abnormal characteristics. published by Jean-Martin Charcot in 1879: Text accompanying image stated, "The strokes forming the letters are very irregular and sinuous, whilst the irregularities and sinuosities are of a very limited width. On a careful examination of this specimen of writing, it will be perceived that the down-strokes are all, with the exception of the first letter, made with comparative firmness and are, in fact, nearly normal—the finer up-strokes, on the contrary, are all tremulous in appearance, and it is to the unsteadiness of these lines that the peculiar character of the writing here is principally due."

Other motor symptoms include:

Neuropsychiatric

Example of reported prevalences of mood problems in PD patients with dementia [1] [8]
Mood problemPrevalence
Depression  58%
Apathy  54%
Anxiety  49%

Parkinson's disease causes neuropsychiatric disturbances, which mainly include cognitive disorders, mood disorders, and behavior problems, and can be as disabling as motor symptoms. [1]

Since L-Dopa, the widely used drug in Parkinson's disease treatment, is decarboxylated by aromatic L-amino acid decarboxylase (AADC), which is found in both dopaminergic and serotonergic neurons, it is possible for serotonergic neurons to convert L-Dopa into dopamine and generate excessive neuronal death by creating reactive oxygen species and quinoproteins. The association of serotonin with mood and cognition may explain some of the side-effects observed in patients treated with L-Dopa due to serotonin deficit. [9] [10]

In most cases, motor symptoms predominate at early PD stages, while cognitive disturbances (such as mild cognitive impairment or dementia) emerge later. [11] The onset of parkinsonism in PD relative to dementia is used as an arbitrary criterion to clinically distinguish Parkinson's disease dementia (PDD) and dementia with Lewy bodies (DLB) using a 'one-year rule'. [11] Dementia onset within 12-months of or at the same time as motor dysfunctions qualified as DLB, whereas in PDD, parkinsonism had to precede dementia by at least one year. [11]

Cognitive disturbances occur even in the initial stages of the disease in some cases. [12] A very high proportion of patients have mild cognitive impairment as the disease advances. [1] Most common deficits in nondemented patients are:

Deficits tend to aggravate with time, developing in many cases into dementia. A person with PD has a six-fold increased risk of developing it, [1] and the overall rate in people with the disease is around 30%. [12] Moreover, prevalence of dementia increases in relation to disease duration, going up to 80%. [12] Dementia has been associated with a reduced quality of life in patients and caregivers, increased mortality, and a higher probability of moving to a nursing home. [12]

Cognitive problems and dementia are usually accompanied by behavior and mood alterations, although these kinds of changes are also more common in those patients without cognitive impairment than in the general population. Most frequent mood difficulties include: [1]

Obsessive–compulsive behaviors (also known as impulse-control disorders) such as craving, binge eating, hypersexuality, pathological gambling, punding, or others, can also appear in PD, and have been related to a dopamine dysregulation syndrome associated with the medications for the disease. [1]

Psychotic symptoms are common in PD, generally associated with dopamine therapy. Symptoms of psychosis, or impaired reality testing, are either hallucinations, typically visual, less commonly auditory, and rarely in other domains including tactile, gustatory, or olfactory, or delusions, that is, irrational beliefs. Hallucinations are generally stereotyped and without emotional content. Initially, patients usually have insight so that the hallucinations are benign in terms of their immediate impact, but have poor prognostic implications, with increased risk of dementia, worsened psychotic symptoms, and mortality. Delusions occur in about 5-10% of treated patients, and are considerably more disruptive, being paranoid in nature, of spousal infidelity or family abandonment. Psychosis is an independent risk factor for nursing-home placement. [23]

Hallucinations can occur in parkinsonian syndromes for a variety of reasons. An overlap exists between PD and dementia with Lewy bodies, so that where Lewy bodies are present in the visual cortex, hallucinations may result. Hallucinations can also be brought about by excessive dopaminergic stimulation. Most hallucinations are visual in nature, often formed as familiar people or animals, and are generally not threatening in nature. Some patients find them comforting; however, their caregivers often find this part of the disease most disturbing, and the occurrence of hallucinations is a major risk factor for hospitalisation. Treatment options consist of modifying the dosage of dopaminergic drugs taken each day, adding an antipsychotic drug such as quetiapine, or offering caregivers a psychosocial intervention to help them cope with the hallucinations.

Sleep

Rapid eye movement sleep is altered in PD as opposed to the shown EEG polysomnographic record representing normal REM. Sleep EEG REM.png
Rapid eye movement sleep is altered in PD as opposed to the shown EEG polysomnographic record representing normal REM.

Sleep problems can be worsened by medications for PD, but they are a core feature of the disease. [1] Sleep dysfunction in PD has significant negative impacts on both patient and carer quality of life. [24] Some common symptoms are:

Perception

Autonomic

Gastrointestinal

Parkinson's Disease causes constipation and gastric dysmotility that is severe enough to endanger comfort and even health. [26] A factor in this is the appearance of Lewy bodies and Lewy neurites even before these affect the functioning of the substantia nigra in the neurons in the enteric nervous system that control gut functions. [27]

Neuro-ophthalmological

PD is related to different ophthalmological abnormalities produced by the neurological changes. [1] [28] Among them are:

Related Research Articles

<span class="mw-page-title-main">Tremor</span> Involuntary muscle contraction

A tremor is an involuntary, somewhat rhythmic, muscle contraction and relaxation involving oscillations or twitching movements of one or more body parts. It is the most common of all involuntary movements and can affect the hands, arms, eyes, face, head, vocal folds, trunk, and legs. Most tremors occur in the hands. In some people, a tremor is a symptom of another neurological disorder.

<span class="mw-page-title-main">Parkinsonism</span> Medical condition

Parkinsonism is a clinical syndrome characterized by tremor, bradykinesia, rigidity, and postural instability. Both hypokinetic as well as hyperkinetic features are displayed by Parkinsonism.These are the four motor symptoms found in Parkinson's disease (PD) – after which it is named – dementia with Lewy bodies (DLB), Parkinson's disease dementia (PDD), and many other conditions. This set of symptoms occurs in a wide range of conditions and may have many causes, including neurodegenerative conditions, drugs, toxins, metabolic diseases, and neurological conditions other than PD.

<span class="mw-page-title-main">Dementia with Lewy bodies</span> Type of progressive dementia

Dementia with Lewy bodies (DLB) is a type of dementia characterized by changes in sleep, behavior, cognition, movement, and regulation of automatic bodily functions. Memory loss is not always an early symptom. The disease worsens over time and is usually diagnosed when cognitive impairment interferes with normal daily functioning. Together with Parkinson's disease dementia, DLB is one of the two Lewy body dementias. It is a common form of dementia, but the prevalence is not known accurately and many diagnoses are missed. The disease was first described on autopsy by Kenji Kosaka in 1976, and he named the condition several years later.

<span class="mw-page-title-main">Rapid eye movement sleep behavior disorder</span> Medical condition

Rapid eye movement sleep behavior disorder or REM behavior disorder (RBD) is a sleep disorder in which people act out their dreams. It involves abnormal behavior during the sleep phase with rapid eye movement (REM) sleep. The major feature of RBD is loss of muscle atonia during otherwise intact REM sleep. The loss of motor inhibition leads to sleep behaviors ranging from simple limb twitches to more complex integrated movements that can be violent or result in injury to either the individual or their bedmates.

<span class="mw-page-title-main">Multiple system atrophy</span> Neurodegenerative disorder

Multiple system atrophy (MSA) is a rare neurodegenerative disorder characterized by tremors, slow movement, muscle rigidity, and postural instability, autonomic dysfunction and ataxia. This is caused by progressive degeneration of neurons in several parts of the brain including the basal ganglia, inferior olivary nucleus, and cerebellum.

<span class="mw-page-title-main">Progressive supranuclear palsy</span> Medical condition

Progressive supranuclear palsy (PSP) is a late-onset neurodegenerative disease involving the gradual deterioration and death of specific volumes of the brain. The condition leads to symptoms including loss of balance, slowing of movement, difficulty moving the eyes, and cognitive impairment. PSP may be mistaken for other types of neurodegeneration such as Parkinson's disease, frontotemporal dementia and Alzheimer's disease. The cause of the condition is uncertain, but involves the accumulation of tau protein within the brain. Medications such as levodopa and amantadine may be useful in some cases.

<span class="mw-page-title-main">Hypokinesia</span> Decreased movement due to basal ganglia dysfunction

Hypokinesia is one of the classifications of movement disorders, and refers to decreased bodily movement. Hypokinesia is characterized by a partial or complete loss of muscle movement due to a disruption in the basal ganglia. Hypokinesia is a symptom of Parkinson's disease shown as muscle rigidity and an inability to produce movement. It is also associated with mental health disorders and prolonged inactivity due to illness, amongst other diseases.

Parkinson-plus syndromes (PPS) are a group of neurodegenerative diseases featuring the classical features of Parkinson's disease with additional features that distinguish them from simple idiopathic Parkinson's disease (PD). Parkinson-plus syndromes are either inherited genetically or occur sporadically.

<span class="mw-page-title-main">Corticobasal degeneration</span> Rare neurodegenerative disease

Corticobasal degeneration (CBD) is a rare neurodegenerative disease involving the cerebral cortex and the basal ganglia. CBD symptoms typically begin in people from 50 to 70 years of age, and typical survival before death is eight years. It is characterized by marked disorders in movement and cognition, and is classified as one of the Parkinson plus syndromes. Diagnosis is difficult, as symptoms are often similar to those of other disorders, such as Parkinson's disease, progressive supranuclear palsy, and dementia with Lewy bodies, and a definitive diagnosis of CBD can only be made upon neuropathologic examination.

In the management of Parkinson's disease, due to the chronic nature of Parkinson's disease (PD), a broad-based program is needed that includes patient and family education, support-group services, general wellness maintenance, exercise, and nutrition. At present, no cure for the disease is known, but medications or surgery can provide relief from the symptoms.

<span class="mw-page-title-main">Frontotemporal dementia and parkinsonism linked to chromosome 17</span> Medical condition

Frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) is an autosomal dominant neurodegenerative tauopathy and Parkinson plus syndrome. FTDP-17 is caused by mutations in the MAPT gene located on the q arm of chromosome 17, and has three cardinal features: behavioral and personality changes, cognitive impairment, and motor symptoms. FTDP-17 was defined during the International Consensus Conference in Ann Arbor, Michigan, in 1996.

<span class="mw-page-title-main">Bradyphrenia</span> Slow mental activity

Bradyphrenia is the slowness of thought common to many disorders of the brain. Disorders characterized by bradyphrenia include Parkinson's disease and forms of schizophrenia consequently causing a delayed response and fatigue. Patients with bradyphrenia may describe or may manifest slowed thought processes, evidenced by increased latency of response and also involve severe memory impairment and poor motor control. The word 'bradyphrenia' originates from the ancient Greek meaning 'slow mind.'

Dopamine-responsive dystonia (DRD) also known as Segawa syndrome (SS), is a genetic movement disorder which usually manifests itself during early childhood at around ages 5–8 years.

<span class="mw-page-title-main">Parkinson's disease</span> Long-term degenerative neurological disorder

Parkinson's disease (PD), or simply Parkinson's, is a chronic degenerative disorder of the central nervous system that affects both the motor system and non-motor systems. The symptoms usually emerge slowly, and as the disease progresses, non-motor symptoms become more common. Early symptoms are tremor, rigidity, slowness of movement, and difficulty with walking. Problems may also arise with cognition, behaviour, sleep, and sensory systems. Parkinson's disease dementia is common in advanced stages.

<span class="mw-page-title-main">Parkinsonian gait</span> Type of gait due to Parkinsons disease

Parkinsonian gait is the type of gait exhibited by patients with Parkinson's disease (PD). It is often described by people with Parkinson's as feeling like being stuck in place, when initiating a step or turning, and can increase the risk of falling. This disorder is caused by a deficiency of dopamine in the basal ganglia circuit leading to motor deficits. Gait is one of the most affected motor characteristics of this disorder although symptoms of Parkinson's disease are varied.

<span class="mw-page-title-main">Kufor–Rakeb syndrome</span> Medical condition

Kufor–Rakeb syndrome (KRS) is an autosomal recessive disorder of juvenile onset also known as Parkinson disease-9 (PARK9). It is named after Kufr Rakeb in Irbid, Jordan. Kufor–Rakeb syndrome was first identified in this region in Jordan with a Jordanian couple's 5 children who had rigidity, mask-like face, and bradykinesia. The disease was first described in 1994 by Najim Al-Din et al. The OMIM number is 606693.

<span class="mw-page-title-main">History of Parkinson's disease</span> History of Parkinsons disease

The history of Parkinson's disease expands from 1817, when British apothecary James Parkinson published An Essay on the Shaking Palsy, to modern times. Before Parkinson's descriptions, others had already described features of the disease that would bear his name, while the 20th century greatly improved knowledge of the disease and its treatments. PD was then known as paralysis agitans. The term "Parkinson's disease" was coined in 1865 by William Sanders and later popularized by French neurologist Jean-Martin Charcot.

Gene therapy in Parkinson's disease consists of the creation of new cells that produce a specific neurotransmitter (dopamine), protect the neural system, or the modification of genes that are related to the disease. Then these cells are transplanted to a patient with the disease. There are different kinds of treatments that focus on reducing the symptoms of the disease but currently there is no cure.

Parkinson's disease dementia (PDD) is dementia that is associated with Parkinson's disease (PD). Together with dementia with Lewy bodies (DLB), it is one of the Lewy body dementias characterized by abnormal deposits of Lewy bodies in the brain.

Rapid eye movement sleep behaviour disorder and Parkinson's disease is rapid eye movement sleep behavior disorder (RBD) that is associated with Parkinson's disease. RBC is linked genetically and neuropathologically to α- synuclein, a presynaptic neuronal protein that exerts deleterious effects on neighbouring proteins, leading to neuronal death. This pathology is linked to numerous other neurodegenerative disorders, such as Lewy bodies dementia, and collectively these disorders are known as synucleinopathies. Numerous reports over the past few years have stated the frequent association of synucleinopathies with REM sleep behaviour disorder (RBD). In particular, the frequent association of RBD with Parkinson's. In the general population the incidence of RBD is around 0.5%, compared to the prevalence of RBD in PD patients, which has been reported to be between 38% and 60%. The diagnosis and symptom onset of RBD typically precedes the onset of motor or cognitive symptoms of PD by a number of years, typically ranging anywhere from 2 to 15 years prior. Hence, this link could provide an important window of opportunity in the implementation of therapies and treatments, that could prevent or slow the onset of PD.

References

  1. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 Jankovic J (April 2008). "Parkinson's disease: clinical features and diagnosis". J. Neurol. Neurosurg. Psychiatry. 79 (4): 368–76. doi: 10.1136/jnnp.2007.131045 . PMID   18344392.
  2. 1 2 Cooper G, Eichhorn G, Rodnitzky RL (2008). "Parkinson's disease". In Conn PM (ed.). Neuroscience in medicine. Totowa: Humana Press. pp. 508–512. ISBN   978-1-60327-454-8.
  3. 1 2 3 4 Samii A, Nutt JG, Ransom BR (May 2004). "Parkinson's disease". Lancet. 363 (9423): 1783–93. doi:10.1016/S0140-6736(04)16305-8. PMID   15172778. S2CID   35364322.
  4. Banich MT, Compton RJ (2011). "Motor control". Cognitive neuroscience. Belmont, CA: Wadsworth, Cengage learning. pp. 108–44. ISBN   978-0-8400-3298-0.
  5. Fung VS, Thompson PD (2007). "Rigidity and spasticity". In Tolosa E, Jankovic JJ (eds.). Parkinson's disease and movement disorders. Hagerstown, MD: Lippincott Williams & Wilkins. pp. 504–13. ISBN   978-0-7817-7881-7.
  6. Rodriguez-Oroz MC, Jahanshahi M, Krack P, et al. (December 2009). "Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms". Lancet Neurol. 8 (12): 1128–39. doi:10.1016/S1474-4422(09)70293-5. PMID   19909911. S2CID   16415964.
  7. Lepoutre A, Devos D, Blanchard-Dauphin A, et al. (2006). "A specific clinical pattern of camptocormia in Parkinson's disease". J. Neurol. Neurosurg. Psychiatry. 77 (11): 1229–34. doi:10.1136/jnnp.2005.083998. PMC   2077366 . PMID   16735399.
  8. Aarsland D, Brønnick K, Ehrt U, et al. (January 2007). "Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress". Journal of Neurology, Neurosurgery, and Psychiatry. 78 (1): 36–42. doi:10.1136/jnnp.2005.083113. PMC   2117797 . PMID   16820421.
  9. Stansley, B. J., & Yamamoto, B. K. (2012). L-dopa-induced dopamine synthesis and oxidative stress in serotonergic cells. Neuropharmacology, 67, 243–251. doi:10.1016/j.neuropharm.2012.11.010
  10. Stansley, B. J., & Yamamoto, B. K. (2015). L-Dopa and Brain Serotonin System Dysfunction. Toxics, 3(1), 75–88. doi:10.3390/toxics3010075
  11. 1 2 3 Saeed, U; Compagnone, J; Aviv, RI; Strafella, AP; Black, SE; Lang, AE; Masellis, M (2017). "Imaging biomarkers in Parkinson's disease and Parkinsonian syndromes: current and emerging concepts". Translational Neurodegeneration. 6 (8): 8. doi: 10.1186/s40035-017-0076-6 . PMC   5370489 . PMID   28360997.
  12. 1 2 3 4 5 6 7 8 9 Caballol N, Martí MJ, Tolosa E (September 2007). "Cognitive dysfunction and dementia in Parkinson disease". Mov. Disord. 22 (Suppl 17): S358–66. doi:10.1002/mds.21677. PMID   18175397. S2CID   3229727.
  13. Reinders, JS (Jan 2008). "A systematic review of prevalence studies of depression in Parkinson's disease". Movement Disorders. 23 (2): 183–9, quiz 313. doi:10.1002/mds.21803. hdl: 1956/4068 . PMID   17987654. S2CID   16613346.
  14. Lieberman A (January 2006). "Depression in Parkinson's disease -- a review". Acta Neurologica Scandinavica. 113 (1): 1–8. doi: 10.1111/j.1600-0404.2006.00536.x . PMID   16367891. S2CID   35349675.
  15. Ishihara L, Brayne C (April 2006). "A systematic review of depression and mental illness preceding Parkinson's disease". Acta Neurologica Scandinavica. 113 (4): 211–20. doi:10.1111/j.1600-0404.2006.00579.x. PMID   16542159. S2CID   249341.
  16. Gustafsson, H (June 2015). "Depression and subsequent risk of Parkinson disease: A nationwide cohort study". Neurology. 84 (24): 2422–9. doi:10.1212/WNL.0000000000001684. PMC   4478031 . PMID   25995056.
  17. McDonald W; Richard, IH; Delong, MR (2003). "Prevalence, Etiology, and Treatment of Depression in Parkinson's Disease". Biol Psychiatry. 54 (3): 363–375. doi:10.1016/S0006-3223(03)00530-4. PMID   12893111. S2CID   45520438.
  18. Leentjens, Albert F. (2015). "Parkinson disease: Depression—risk factor or early symptom in Parkinson disease?". Nature Reviews Neurology. 11 (8): 432–433. doi:10.1038/nrneurol.2015.126. PMID   26215622. S2CID   11364065.
  19. Leentjens, Albert F. G.; Moonen, Anja J. H.; Dujardin, Kathy; Marsh, Laura; Martinez-Martin, Pablo; Richard, Irene H.; Starkstein, Sergio E.; Köhler, Sebastian (2013-09-17). "Modeling depression in Parkinson disease Disease-specific and nonspecific risk factors". Neurology. 81 (12): 1036–1043. doi:10.1212/WNL.0b013e3182a4a503. ISSN   0028-3878. PMC   3795592 . PMID   23946309.
  20. Menza, Matthew Combating Depression in Parkinson's Disease. Parkinson's Disease Foundation News & Review. Spring 2009.
  21. Menza MA. Psychiatric symptoms associated with Parkinson disease. Drug Benefit Trends. 2010;22:58-60.
  22. The National Collaborating Centre for Chronic Conditions, ed. (2006). "Non-motor features of Parkinson's disease". Parkinson's Disease. London: Royal College of Physicians. pp. 113–33. ISBN   978-1-86016-283-1.
  23. Friedman JH (June 2010). "Parkinson's disease psychosis 2010: A review article". Parkinsonism Relat Disord. 16 (9): 553–60. doi:10.1016/j.parkreldis.2010.05.004. PMID   20538500.
  24. Hunt, Jeremy; Coulson, Elizabeth J.; Rajnarayanan, Rajendram; Oster, Henrik; Videnovic, Aleksandar; Rawashdeh, Oliver (2022-01-09). "Sleep and circadian rhythms in Parkinson's disease and preclinical models". Molecular Neurodegeneration. 17 (1): 2. doi: 10.1186/s13024-021-00504-w . ISSN   1750-1326. PMC   8744293 . PMID   35000606.
  25. Gupta AK, Bluhm R (January 2004). "Seborrheic dermatitis". Journal of the European Academy of Dermatology and Venereology. 18 (1): 13–26, quiz 19–20. doi:10.1111/j.1468-3083.2004.00693.x. PMID   14678527. S2CID   45180745.
  26. Pfeiffer RF (February 2003). "Gastrointestinal dysfunction in Parkinson's disease". Lancet Neurology. 2 (2): 107–16. doi:10.1016/S1474-4422(03)00307-7. PMID   12849267. S2CID   21009040.
  27. Lebouvier T, Chaumette T, Paillusson S, et al. (September 2009). "The second brain and Parkinson's disease". The European Journal of Neuroscience. 30 (5): 735–41. doi:10.1111/j.1460-9568.2009.06873.x. PMID   19712093. S2CID   1024997.
  28. 1 2 3 Armstrong RA (March 2008). "Visual signs and symptoms of Parkinson's disease". Clin Exp Optom. 91 (2): 129–38. doi:10.1111/j.1444-0938.2007.00211.x. PMID   18271776. S2CID   26202780.
  29. Gitchel GT, Wetzel PA, Baron MS (2012). "Pervasive ocular tremor in patients with Parkinson disease". Arch Neurol. 69 (8): 1011–7. doi:10.1001/archneurol.2012.70. PMID   22490323.
  30. Uc EY; Rizzo, M; Anderson, SW; Sparks, J; Rodnitzky, RL; Dawson, JD (2006). "Impaired visual search in drivers with Parkinson's disease". Annals of Neurology . 60 (4): 407–13. doi:10.1002/ana.20958. PMID   16969860. S2CID   40915704.